Immuno-Biological Laboratories Co (TSE:4570) Net Margin %: 36.07% (As of Mar. 2026)


TSE:4570 Immuno-Biological Laboratories Co Ltd TSE:4570
59 GF Score
Price 円969.00
GF Value 円576.66
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immuno-Biological Laboratories Co Net Margin %?

Immuno-Biological Laboratories Co TSE:4570 -2.02% 59 Net Margin % is 36.07% as of Mar. 2026. GuruFocus rates TSE:4570 with a GF Score™ of 59/100 and a GF Value™ of 円576.66 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Immuno-Biological Laboratories Co ranks better than 91.53% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Immuno-Biological Laboratories Co's Net Income for the six months ended in Mar. 2026 was 円187 Mil. Immuno-Biological Laboratories Co's Revenue for the six months ended in Mar. 2026 was 円519 Mil. Therefore, Immuno-Biological Laboratories Co's net margin for the quarter that ended in Mar. 2026 was 36.07%.

The historical rank and industry rank for Immuno-Biological Laboratories Co's Net Margin % or its related term are showing as below:

TSE:4570' s Net Margin % Range Over the Past 10 Years
Min: -282.45   Med: -28.94   Max: 32.74
Current: 32.74


TSE:4570's Net Margin % is ranked better than
91.53% of 945 companies
in the Biotechnology industry
Industry Median: -89.33 vs TSE:4570: 32.74

Immuno-Biological Laboratories Co  (TSE:4570) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Immuno-Biological Laboratories Co Net Margin % Related Terms


Immuno-Biological Laboratories Co Net Margin % Historical Data

* Premium members only.

The historical data trend for Immuno-Biological Laboratories Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuno-Biological Laboratories Co Net Margin % Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.96 -36.46 22.86 25.69 32.74

Immuno-Biological Laboratories Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.43 16.10 33.79 29.17 36.07

TSE:4570 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuno-Biological Laboratories Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's Net Margin % falls into.


TSE:4570
59GF Score
Immuno-Biological Laboratories Co Ltd TSE:4570
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immuno-Biological Laboratories Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Immuno-Biological Laboratories Co's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin=Net Income (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=329.015/1004.987
=32.74 %

Immuno-Biological Laboratories Co's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=187.391/519.498
=36.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 36.07% mean?
Immuno-Biological Laboratories Co (TSE:4570) has a Net Margin % of 36.07% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Immuno-Biological Laboratories Co and its competitors. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #80 out of 945 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Immuno-Biological Laboratories Co's Net Margin % too high?
Immuno-Biological Laboratories Co's current Net Margin % is 36.07%. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #80 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #80 out of 945 companies for Net Margin %. This places Immuno-Biological Laboratories Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Immuno-Biological Laboratories Co and its competitors. Immuno-Biological Laboratories Co's current Net Margin % is 36.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円576.66, compared to a current price of 円969.00 — trading 68% above its estimated fair value. The current Net Margin % is 36.07%. Immuno-Biological Laboratories Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Net Margin % is 36.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?

Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued. The current stock price of 円969.00 is trading 68% above its estimated GF Value™ of 円576.66. GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.

Key valuation signals for TSE:4570:

  • Net Margin %: 36.07%
  • GF Value™: 円576.66 vs. price of 円969.00 (68% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immuno-Biological Laboratories Co Business Description

Address 1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
59GF Score

Get the complete analysis for TSE:4570

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円969.00
Price
円576.66
GF Value